We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Explore the cost of Gattex (teduglutide) for Short Bowel Syndrome. This guide covers factors influencing Gattex price, insurance coverage, patient assistance programs, and how to afford this vital medication.
Living with a chronic and debilitating condition like Short Bowel Syndrome (SBS) presents a unique set of challenges. For many patients, managing SBS symptoms and improving intestinal function is dependent on specialized treatments, with Gattex (teduglutide) being a cornerstone therapy. While Gattex offers significant hope by potentially reducing or even eliminating the need for parenteral nutrition (PN) or intravenous (IV) fluids, its high cost can be a major barrier to access. This comprehensive guide aims to demystify the cost of Gattex, explore the factors influencing its price, delve into insurance coverage options, and highlight patient assistance programs designed to make this vital medication more affordable.
Understanding the financial landscape of Gattex is crucial for patients, caregivers, and healthcare providers alike. By providing detailed insights into the drug itself, the condition it treats, and the various avenues for financial support, we hope to empower individuals navigating the complexities of SBS treatment.
Gattex, with the generic name teduglutide, is a prescription medication used to treat adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support (PN/IV fluids). It belongs to a class of drugs known as glucagon-like peptide-2 (GLP-2) analogs.
Teduglutide works by mimicking the action of GLP-2, a naturally occurring hormone in the body that helps regulate intestinal function. Specifically, Gattex helps to:
Gattex is administered as a subcutaneous injection once daily. It is a long-term treatment, and its effectiveness is monitored through changes in parenteral support requirements and overall patient health.
To fully appreciate the value and necessity of Gattex, it's important to understand Short Bowel Syndrome itself.
Short Bowel Syndrome is a rare, complex malabsorption disorder that occurs when a significant portion of the small intestine is either surgically removed or congenitally absent/non-functional. The small intestine is responsible for absorbing most of the nutrients and fluids from food. When its length is significantly reduced, the body cannot absorb enough water, vitamins, minerals, protein, fat, and calories to sustain itself, leading to severe nutritional deficiencies and dehydration.
The symptoms of SBS can vary depending on the amount and specific sections of the small intestine removed, as well as the presence of a colon. Common symptoms include:
SBS is typically a consequence of extensive surgical resection of the small intestine. Common causes include:
Diagnosing SBS involves a comprehensive evaluation, including:
Treatment for SBS is highly individualized and aims to maximize nutrient absorption, prevent complications, and improve quality of life. Options include:
Gattex is a groundbreaking medication for SBS, but its specialized nature and complex manufacturing process contribute to its exceptionally high cost. For many patients, understanding the financial implications is as critical as understanding the drug's mechanism of action.
Several factors contribute to the high price tag of Gattex:
Confused about whether CBD can get you high? Understand the difference between CBD and THC, their effects on your body, and what to look for in safe, non-intoxicating CBD products.
April 1, 2026
Learn about anticoagulants and antiplatelet drugs, often called blood thinners. Understand how they prevent blood clots, when they're prescribed, their side effects, and essential safety tips for Indian readers.
April 1, 2026

Confused about Plan B and abortion pills? Understand the key differences, how they work, and their effectiveness for informed reproductive health decisions.
April 1, 2026